FINWIRES · TerminalLIVE
FINWIRES

リサーチアラート:CFRAはGEヘルスケアテクノロジーズ社の株式に対する「ホールド」評価を維持。

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。2027年のEPS予想5.51ドルの11.8倍に基づき、目標株価を87ドルから65ドルに引き下げます。これは、現在の平均予想PER18.1倍を大きく下回る水準です。2026年の調整後EPS予想も4.96ドルから4.86ドルに引き下げました。これは、下方修正後のガイダンスレンジ4.80ドル~5.00ドル(従来は4.95ドル~5.15ドル)の下限値に相当します。GEヘルスケアは、第1四半期のオーガニック売上高成長率が前年同期比2.9%となり、予想の上限に達しました。しかし、収益性指標は期待外れで、調整後EPSは0.99ドルと予想を下回り、調整後EBITマージンは前年同期比150ベーシスポイント低下しました。これは主に、PDx事業における個別のサプライヤー問題と、予想外のインフレコストの上昇によるものです。その結果、GEHCは利益とキャッシュフローの見通しを引き下げましたが、これは賢明な判断だと考えます。戦略的には、GEHCは強力なイノベーションパイプラインを推進しており、Inteleradの買収を完了し、イメージング部門とAVS部門を統合して新たな部門を設立する組織再編を発表しており、成長を加速させる可能性を秘めていると考えています。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Cincinnati Financial Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target price by $7 to $185, valuing CINF shares (currently yielding 2%) at 20x our 2027 operating EPS estimate of $9.15 (raised by $0.10) and at 21.5x our 2026 EPS estimate of $8.60 (raised by $0.10), versus its five-year average forward multiple of 21x and peer average. CINF posted Q1 operating EPS of $2.10 versus a $0.24 operating loss per share a year ago, matching our estimate and topping the $1.94 consensus view, amid 12% higher operating revenues due to 11% premium growth and 14% higher net investment income, with written premium growth of 7% likely at the upper end of peer averages. We believe CINF's competitive strengths include its facile underwriting style and ability to allocate underwriting capital to areas with the most promising fundamentals, positioning it well despite increasingly competitive market conditions. CINF's ability to consistently produce above-peer growth and underwriting profitability will support the shares' premium valuation versus peers, in our view.

$CINF
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Linde Plc

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our 12-month target by $48 to $537, using a P/E of 27.1x, equal to LIN's average forward P/E over the last three years. We raise our 2026 EPS estimate by $0.05 to $18.03 and 2027 by $0.26 to $19.81. LIN reported Q1 adj. EPS of $4.33, beating consensus by $0.06, with 30% operating margins and 24% ROC demonstrating the resilience of its business model. Management raised the low end of full-year guidance to $17.60-$17.90 (7%-9% growth), citing confidence despite geopolitical headwinds. The $7.1B project backlog should reach $8B+ by year-end, driven by Electronics projects supporting AI chip manufacturing. Americas volumes grew 2% Y/Y with double-digit hardgoods growth, though EMEA remains challenged by weak industrial activity. Commercial space is emerging as a significant growth driver, with aerospace sales up double-digits. Helium supply tightness presents upside opportunity beyond guidance. We think shares are fully valued at 25.6x our 2027 EPS estimate, limiting upside potential in the near term.

$LIN
Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Silgan Holdings Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target by $13 to $46, based on an EV/EBITDA of 8.9x our 2026 EBITDA estimate, in line with SLGN's three-year average multiple. We increase our 2026 EPS estimate by $0.05 to $3.90 and raise 2027's by $0.05 to $4.20. Metal containers started the year strong, up 2% Y/Y, with pet food product volume up 11%. Management continues to see a long runway for growth in the fragrance, beauty, and health care category now that it is fully integrated into the Weener portfolio. We anticipate further product launches and customer partnerships in 2027, driving growth in this space. Dispensing and specialty closures headwinds are due to higher-cost inventory with volumes adversely affected by severe weather events in North America. Management also noted that volume is likely to improve in 2H 2026 after securing new business wins that have yet to be commercialized but were secured earlier this year.

$SLGN